APLS · Insider Trading
Apellis Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by APLS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-14 | Caroline Baumal | Chief Medical Officer | MIXED | −137,832 | — |
| 2026-05-14 | Cedric Francois | Chief Executive Officer | MIXED | −2,156,117 | — |
| 2026-05-14 | David O. Watson | General Counsel | MIXED | −317,949 | — |
| 2026-05-14 | Craig A Wheeler | Director | MIXED | −47,515 | — |
| 2026-05-14 | Kelley Boucher | Chief People Officer | MIXED | −255,608 | — |
| 2026-05-14 | Stephanie Monaghan O'Brien | Director | MIXED | −55,604 | — |
| 2026-05-14 | Mark Jeffrey DeLong | Chief Business & Strat Officer | MIXED | −185,969 | — |
| 2026-05-14 | Keli Walbert | Director | MIXED | −33,344 | — |
| 2026-05-14 | Nur Nicholson | Chief Technical Officer | MIXED | −204,277 | — |
| 2026-05-14 | Gerald Chan | Director | MIXED | −49,854 | — |
| 2026-05-14 | Pascal Deschatelets | Chief Scientific Officer | MIXED | −1,222,627 | — |
| 2026-05-14 | Alec Machiels | Director | MIXED | −817,250 | — |
| 2026-05-14 | Timothy Eugene Sullivan | Chief Financial Officer | MIXED | −323,770 | — |
| 2026-05-14 | Paul R. Fonteyne | Director | MIXED | −54,854 | — |
| 2026-05-14 | Leslie Meltzer | Chief Research and Development | MIXED | −214,048 | — |
| 2026-05-14 | Mikael Dolsten | Director | MIXED | −28,624 | — |
| 2026-05-14 | James George Chopas | VP/Chief Accounting Officer | MIXED | −104,361 | — |
| 2026-05-14 | A. Sinclair Dunlop | Director | MIXED | −181,878 | — |
| 2026-05-01 | Caroline Baumal | Chief Medical Officer | G | −900 | — |
| 2026-04-20 | Timothy Eugene Sullivan | Chief Financial Officer | G | — | — |
| 2026-04-08 | Stephanie Monaghan O'Brien | Director | J | +5,750 | — |
| 2026-03-13 | Cedric Francois | Chief Executive Officer | G | — | — |
| 2026-03-03 | Mikael Dolsten | Director | A | +14,312 | — |
| 2026-02-13 | Mark Jeffrey DeLong | Chief Business & Strat Officer | Sell | −368 | −$8.15K |
| 2026-02-05 | Cedric Francois | Chief Executive Officer | M | +8,840 | +$33.24K |
| 2026-01-30 | Cedric Francois | Chief Executive Officer | A | +195,952 | — |
| 2026-01-30 | David O. Watson | General Counsel | A | +55,986 | — |
| 2026-01-30 | Timothy Eugene Sullivan | Chief Financial Officer | A | +58,140 | — |
| 2026-01-30 | Nur Nicholson | Chief Technical Officer | A | +45,220 | — |
| 2026-01-30 | Leslie Meltzer | Chief Research and Development | A | +45,220 | — |
| 2026-01-30 | Pascal Deschatelets | Chief Scientific Officer | A | +25,840 | — |
| 2026-01-30 | Mark Jeffrey DeLong | Chief Business & Strat Officer | A | +36,606 | — |
| 2026-01-30 | James George Chopas | VP/Chief Accounting Officer | A | +16,150 | — |
| 2026-01-30 | Kelley Boucher | Chief People Officer | A | +30,146 | — |
| 2026-01-23 | David O. Watson | General Counsel | Sell | −7,832 | −$170.47K |
| 2026-01-23 | Timothy Eugene Sullivan | Chief Financial Officer | Sell | −10,287 | −$223.90K |
| 2026-01-23 | Nur Nicholson | Chief Technical Officer | Sell | −7,725 | −$168.14K |
| 2026-01-23 | Cedric Francois | Chief Executive Officer | Sell | −27,192 | −$591.84K |
| 2026-01-23 | Pascal Deschatelets | Chief Scientific Officer | Sell | −5,928 | −$129.03K |
| 2026-01-23 | Mark Jeffrey DeLong | Chief Business & Strat Officer | Sell | −3,371 | −$73.37K |
| 2026-01-23 | James George Chopas | VP/Chief Accounting Officer | Sell | −2,064 | −$44.92K |
| 2026-01-23 | Caroline Baumal | Chief Medical Officer | Sell | −2,797 | −$60.88K |
| 2026-01-21 | David O. Watson | General Counsel | Sell | −2,475 | −$48.99K |
| 2026-01-21 | Timothy Eugene Sullivan | Chief Financial Officer | Sell | −2,892 | −$57.24K |
| 2026-01-21 | Nur Nicholson | Chief Technical Officer | Sell | −2,203 | −$43.60K |
| 2026-01-21 | Cedric Francois | Chief Executive Officer | Sell | −8,182 | −$161.95K |
| 2026-01-21 | Pascal Deschatelets | Chief Scientific Officer | Sell | −909 | −$17.99K |
| 2026-01-21 | Mark Jeffrey DeLong | Chief Business & Strat Officer | Sell | −1,334 | −$26.40K |
| 2026-01-21 | James George Chopas | VP/Chief Accounting Officer | Sell | −726 | −$14.37K |
| 2026-01-21 | Caroline Baumal | Chief Medical Officer | Sell | −1,882 | −$37.25K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Cedric Francois | Chief Executive Officer | 195,952 | $8.04M |
| Adam J. Townsend | Chief Commercial Officer | 84,050 | $3.45M |
| Karen Lewis | Chief People Officer | 70,251 | $2.88M |
| Jeffrey Eisele | Chief Development Officer | 55,312 | $2.27M |
| Nur Nicholson | Chief Technical Officer | 24,284 | $996.37K |
| James George Chopas | VP/Chief Accounting Officer | 8,075 | $331.32K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the APLS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.